Matthew A. Powell, MD:The exciting combinations out there, I think, initially stem from the olaparib/cediranib discussion, where you have an antivascular agent combined with a PARP inhibitor, seeing very nice response rates and progression-free survival benefits both in aBRCApopulation and a wild type population. This has been built upon now with olaparib/bevacizumab. We have some early signals that there’s nice, maybe even synergistic-type, effects. As mentioned earlier, the TOPACIO trial looking at niraparib plus a PD-1 inhibitorthe immunotherapies combined with PARP inhibitors—also seems to be very exciting. I imagine we’ll see all 3 of those agents combined where we have antivascular, PD, and PARP. Again, drugs with cross-resistant toxicities that likely can be combined in a nonchemotherapy fashion, all targeted therapy. I think these may be very nice noncytotoxic chemotherapy options that we have to offer our patients.
I’m very excited at this time for our patients with ovarian cancer. We have a lot of options. These combinations are quite exciting. I think the antibodydrug conjugates also are coming into play, and perhaps combining these with immunotherapy agents, with PARP agents also, is going to be 1 more part of our armamentarium. When to use these drugswe still need to investigate that. As we mentioned, some of the up-front trials now, first-line maintenance strategies: Is that the right place to put these agents? We don’t know yet, and I think that it’s very exciting to see some of these data come out. I think ASCO 2018 is going to shed a lot of light on some new therapies we have for our patients and I hope help more and more patients with ovarian cancer.
Transcript edited for clarity.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More